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ABSTRACT Glycans play diverse biological roles, ranging from structural and regu-
latory functions to mediating cellular interactions. For pathogens, they are also often
required for virulence and survival in the host. In Cryptococcus neoformans, an op-
portunistic pathogen of humans, the acidic monosaccharide glucuronic acid (GlcA) is
a critical component of multiple essential glycoconjugates. One of these glycoconju-
gates is the polysaccharide capsule, a major virulence factor that enables this yeast
to modulate the host immune response and resist antimicrobial defenses. This al-
lows cryptococci to colonize the lung and brain, leading to hundreds of thousands
of deaths each year worldwide. Synthesis of most glycans, including capsule polysac-
charides, occurs in the secretory pathway. However, the activated precursors for this
process, nucleotide sugars, are made primarily in the cytosol. This topological prob-
lem is resolved by the action of nucleotide sugar transporters (NSTs). We discovered
that Uut1 is the sole UDP-GlcA transporter in C. neoformans and is unique among
NSTs for its narrow substrate range and high afﬁnity for UDP-GlcA. Mutant cells with
UUT1 deleted lack capsule polysaccharides and are highly sensitive to environmental
stress. As a result, the deletion mutant is internalized and cleared by phagocytes
more readily than wild-type cells are and is completely avirulent in mice. These ﬁnd-
ings expand our understanding of the requirements for capsule synthesis and cryp-
tococcal virulence and elucidate a critical protein family.
IMPORTANCE Cryptococcus neoformans causes lethal meningitis in almost two hun-
dred thousand immunocompromised patients each year. Much of this fungal patho-
gen’s ability to resist host defenses and cause disease is mediated by carbohydrate
structures, including a complex polysaccharide capsule around the cell. Like most
eukaryotic glycoconjugates, capsule polysaccharides are made within the secretory
pathway, although their precursors are generated in the cytosol. Speciﬁc transport-
ers are therefore required to convey these raw materials to the site of synthesis. One
precursor of particular interest is UDP-glucuronic acid, which donates glucuronic
acid to growing capsule polysaccharides. We discovered a highly speciﬁc, high-
afﬁnity transporter for this molecule. Deletion of the gene encoding this unusual
protein abolishes capsule synthesis, alters stress resistance, and eliminates fungal vir-
ulence. In this work, we have identiﬁed a novel transporter, elucidated capsule syn-
thesis and thereby aspects of fungal pathogenesis, and opened directions for poten-
tial antifungal therapy.
KEYWORDS Cryptococcus neoformans, UDP-glucuronic acid, fungal pathogenesis,
glycan synthesis, nucleotide sugar transporter, polysaccharide capsule
UDP-glucuronic acid (UDP-GlcA) is a critical precursor for essential glycoconjugatesacross biological kingdoms, ranging from mammalian glycosaminoglycans and
plant cell wall polysaccharides to bacterial capsule glycoglycerolipids (1–3). Aberrant
UDP-GlcA synthesis or subcellular localization leads to severe impairments such as
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Schneckenbecken dysplasia in humans (4) and virulence defects in bacterial pathogens
(5–7).
Our interest in UDP-GlcA stems from its role in the fungal pathogen Cryptococcus
neoformans. This opportunistic yeast colonizes the lungs and disseminates to the brains
of immunocompromised individuals, where it causes meningoencephalitis that is
responsible for roughly two hundred thousand deaths per year (8–10). UDP-GlcA is a
key biosynthetic precursor of cryptococcal polysaccharides. These complex polymers
associate with the cell wall to form the cryptococcal capsule, which provides a physical
barrier against host immune defenses. These polysaccharides are also shed into the
extracellular space (11), where they impede host defenses by interfering with phago-
cytosis and clearance of the yeast, inhibiting the production of proinﬂammatory
cytokines, depleting complement components, and reducing leukocyte migration to
sites of inﬂammation (12).
The capsule consists of two complex polysaccharides, glucuronoxylomannan (GXM)
and glucuronoxylomannogalactan (GXMGal). GXM, which constitutes 90% of the cap-
sule by mass, is a repeating polymer with a mannose (Man) backbone that is partially
acetylated and is substituted with monosaccharide side chains of glucuronic acid (GlcA)
and xylose (Xyl) (13). The remaining 10% of the capsule mass is made up of GXMGal,
which is a linear galactose (Gal) polymer bearing both single galactofuranose (Galf)
residues and galactomannan side chains substituted with a variable number of GlcA
and Xyl residues (14–16). Overall, GlcA comprises roughly 16% and 7% of the residues
in GXM and GXMGal, respectively, and is responsible for their acidic nature.
Both GXM and GXMGal, like most other eukaryotic glycans, are believed to be
assembled in the secretory pathway (17). However, nucleotide sugars, which donate
individual sugar moieties to growing glycan structures, are synthesized primarily in the
cytosol (18). The endoplasmic reticulum (ER) and Golgi membranes, therefore, consti-
tute physical barriers that prevent substrate access to biosynthetic enzymes. Nucleotide
sugar transporters (NSTs) provide a solution to this topological problem by translocat-
ing activated sugars into the luminal space in exchange for the corresponding nucle-
oside monophosphates (19, 20). In this way, NSTs enable luminal glycan biosynthesis.
Predicted protein sequence is not a reliable predictor of NST substrate speciﬁcity.
For example, NSTs with almost 50% amino acid identity have been reported to
transport distinct substrates, while others with only 20% identity appear to translocate
the same substrate (21). Further complicating the picture, individual NSTs range from
highly speciﬁc proteins that recognize a single substrate to less restrictive ones that
transport up to four substrates, and NSTs with overlapping but nonidentical substrate
afﬁnities can be found in a single cell (22–28). Finally, associated glycan synthetic
enzymes and subcellular localization may also inﬂuence the activity of a given NST (29,
30). All of these factors make it a challenge to identify and characterize the full
complement of NSTs in a cell type of interest, impeding our ability to fully deﬁne critical
glycan synthetic processes.
Mutant C. neoformans strains incapable of synthesizing UDP-GlcA do not produce
capsule or cause disease in mice, demonstrating the importance of GlcA in cryptococcal
biology and pathogenesis (31, 32). Despite this, the NST(s) responsible for transporting
its donor, UDP-GlcA, has never been identiﬁed in C. neoformans. Here we show that
C. neoformans Uut1 is a UDP-GlcA transporter by using an in vitro assay to directly
demonstrate its activity; we also characterize its speciﬁcity and kinetic properties. We
further show that cells lacking Uut1 exhibit marked growth defects and metabolic
abnormalities, which correlate with greater phagocytosis by host macrophages and
quicker clearance of infection in vitro and in vivo. Uut1 is thus a critical protein for
cryptococcal biosynthetic processes and is required for multiple aspects of C. neofor-
mans virulence.
RESULTS
To identify the cryptococcal UDP-GlcA transporter, we ﬁrst used BLASTP to search
the C. neoformans genome for predicted proteins with homology to known UDP-GlcA
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transporters. Although we found no homologs of the transporters from Caenorhabditis
elegans, Homo sapiens, or Drosophila melanogaster, we did ﬁnd a predicted ortholog of
the Arabidopsis thaliana transporter UUAT1 (33), which we termed Uut1 (CNAG_06230).
Similar to other NSTs, Uut1 is predicted to have an even number of transmembrane
domains (here 10) such that the N and C termini are on the same side of the membrane,
likely in the cytosol (see Fig. S1 in the supplemental material). Phylogenetic analysis of
Uut1 places it closest to UUAT1 (Fig. 1), and more distant from other UDP-GlcA
transporters and from known cryptococcal NSTs. Notably, Uut1 and UUAT1 share only
16% amino acid identity, although as discussed above, homology is a poor predictor of
substrate speciﬁcity in this family of proteins.
If Uut1 is indeed a nucleotide sugar transporter that supplies precursors for poly-
saccharide synthesis, we expect it to reside in the secretory pathway. To test this, we
took advantage of existing markers and facile imaging methods in the model yeast
Saccharomyces cerevisiae and expressed FLAG-tagged Uut1 (FLAG-Uut1) under a
copper-inducible promoter in that system. Immunoﬂuorescence (IF) staining showed
that the tagged protein appeared to colocalize with an ER marker (Kar2p/BiP) but not
with the late Golgi marker Sec7 (34) (Fig. 2; see Discussion). A KXKXX motif near the C
terminus (Fig. S1) may be involved in this localization. Such motifs mediate the retrieval
FIG 1 Evolutionary conservation of UDP-GlcA transporters. Phylogenetic relationships of C. neoformans
(Cn) nucleotide sugar transporters (NSTs) and other UDP-GlcA transporters (shown in boldface type) from
Caenorhabditis elegans (Ce), Homo sapiens (Hs), Drosophila melanogaster (Dm), and Arabidopsis thaliana
(At). Tree reconstruction was performed with the Phylogeny.fr web server (62, 63) using MUSCLE, PhyML,
and TreeDyn software. Branch lengths are drawn to scale.
FIG 2 Cryptococcal Uut1 colocalizes with the ER marker Kar2p/BiP (A), but not with the late Golgi marker
Sec7 (B). S. cerevisiae cells expressing Sec7-3xGFP (GFP stands for green ﬂuorescent protein) transformed
with vector alone (Vector) or vector expressing FLAG-tagged Uut1 (FLAG-Uut1) were stained with DAPI
and probed with the indicated antibodies. Bright-ﬁeld (BF), single-channel, and merged images are
shown, and all images have the same magniﬁcation (bars, 1 m). The colors indicate the following: blue,
DAPI; red, anti-FLAG (-FLAG); green, anti-GFP (-GFP) and anti-Kar2p/BiP (-Kar2p). Images are repre-
sentative of three independent immunoﬂuorescence experiments.
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of type I transmembrane proteins from downstream membranes to the ER (35, 36),
although the Uut1 sequence (Fig. S1) is atypical in that it is followed by three additional
amino acids.
To deﬁne the role of Uut1 in cryptococcal biology, we deleted the corresponding
gene (UUT1). Even when the resulting mutant was grown in capsule-inducing condi-
tions (see Materials and Methods), we detected no capsule by negative staining
(Fig. 3A) or by staining with ﬂuorophore-conjugated anti-GXM antibodies (Fig. 3B). We
also detected no GXM shed into the growth medium by enzyme-linked immunosor-
bent assay (ELISA) (Fig. 3C) or by immunoblotting (Fig. 3D), and the mutant cells
appeared clumpy compared to the wild type (WT) (Fig. 3A and B). All of these
phenotypes were consistent with those of the acapsular cap59Δ strain and were
reversed when the deletion was complemented with the wild-type gene at the original
locus (Fig. 3, UUT1). We obtained similar results for capsule staining, GXM shedding
ELISA, and GXM immunoblotting with additional antibodies (Table S1). As far as we can
determine, therefore, cells lacking Uut1 are completely acapsular.
The absence of capsule on cells lacking Uut1 suggested that this putative nucleotide
transporter translocates a major capsule substrate(s). The components of GXM and
FIG 3 The uut1Δ mutant does not produce capsule. (A) Wild-type (WT), uut1Δ, and complemented uut1Δ (UUT1)
strains were cultured under capsule-inducing conditions (see Materials and Methods) for 24 h and then visualized
by light microscopy after negative staining with India ink. Bar  5 m. (B) Cells from the indicated strains were
incubated with calcoﬂuor white (CFW; blue) to stain the cell wall and with MAb 3C2 (red) to visualize the capsule.
Bright-ﬁeld, single-channel gray scale, and merged images are shown. Bar  5 m. (C) Shed capsule polysaccha-
ride, from two independent deletions and control strains, was quantitated by ELISA (see Materials and Methods).
Values are means  standard errors of the means (SEMs) (error bars) from three independent experiments. Values
that are signiﬁcantly different (P  0.01) by one-way ANOVA and Tukey’s posthoc test from the value for the WT
strain are indicated by an asterisk. ND, not detected. (D) Conditioned medium from the indicated strains was
resolved on an agarose gel, transferred to a nylon membrane, and analyzed by immunoblotting with anti-GXM
MAb 3C2 as in reference 69.
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GXMGal are Man, Gal, Xyl, Galf, and GlcA. We previously identiﬁed two transporters of
GDP-Man (30, 37), and there is a known UDP-Gal transporter (38, 39), so we hypothe-
sized that those were less likely to be substrates of Uut1. Additionally, even completely
abrogating synthesis of UDP-Xyl or UDP-Galf yields hypo- or normocapsular cells,
respectively (15, 32, 40), rather than the acapsular cells observed for the uut1Δ mutant;
this argued against these capsule donors as Uut1 substrates. This reasoning left
UDP-GlcA as the best candidate substrate, which was further supported by the obser-
vation that cells unable to synthesize UDP-GlcA are acapsular (31, 32).
To test our hypothesis that Uut1 transports UDP-GlcA, we directly assayed its activity
in vitro. For these studies, we ﬁrst prepared microsomes from S. cerevisiae heterolo-
gously expressing V5-tagged Uut1. We then reconstituted the microsomal protein in
proteoliposomes, which were preloaded with UMP or GMP to serve as antiport sub-
strates. After conﬁrmation of Uut1-V5 expression by immunoblotting (Fig. S2), the
proteoliposomes were incubated with a mixture of nucleotide sugars, subjected to gel
ﬁltration to remove any that were not imported, and analyzed by liquid chromato-
graphy-tandem mass spectrometry (LC-MS/MS). UDP-GlcA was the only cryptococcal
nucleotide sugar that was transported over background by Uut1-bearing proteolipo-
somes preloaded with UMP (Fig. 4A). This transport was saturable with time and
substrate concentration (Fig. 4C and D) and had an apparent Km of 0.6  0.1 M and
Vmax of 1.1  0 nM s1 (mean  standard error of the mean [SEM] from four
independent experiments) with a turnover rate of 0.08 s1. We also observed minor
transport of UDP-galacturonic acid and UDP-arabinofuranose, but those substrates
have never been reported in C. neoformans and were not detected in our analyses (see
below). We observed no transport of any assayed nucleotide sugar when the proteo-
liposomes were preloaded with GMP (Fig. 4B).
We next wondered whether eliminating UDP-GlcA transport would alter cellular
nucleotide sugar metabolism. UDP-GlcA is synthesized from UDP-Glc by UDP-Glc
dehydrogenase (Ugd1), and it may be decarboxylated by UDP-Xyl synthase (Uxs1) to
produce UDP-Xyl; this product inhibits Ugd1 to regulate the pathway (Fig. 5A). Our
measurements of nucleotide sugar content (see Materials and Methods) showed that
the level of UDP-Glc in uut1Δ cells was about 4-fold higher than in WT cells (Fig. 5B). The
levels of UDP-GlcA and UDP-Xyl, in contrast, were not signiﬁcantly different in the
mutant and WT cells (Fig. 5B).
We next examined the cellular level of UDP-GlcA when C. neoformans was incubated
for 24 h under conditions that induce capsule synthesis, which we expected to require
increased UDP-GlcA. Surprisingly, the overall concentration of UDP-GlcA remained
constant under these conditions (4  2 pmol/mg [wet weight]; mean  standard
deviation [SD] from four independent experiments). Consistent with this observation,
transcriptome sequencing (RNA-seq) studies showed no change in UGD1 transcription
over this interval (Fig. 6). However, under the same conditions, UUT1 expression was
upregulated 28-fold (Fig. 6). It thus appears that the increased demand for UDP-GlcA is
satisﬁed by greater transport in the context of adequate cytosolic pools.
GXM and GXMGal are the only C. neoformans glycans known to contain glucuronic
acid, although not all cryptococcal glycoconjugates have been extensively proﬁled.
Furthermore, the UDP-GlcA synthase mutant, the ugd1Δ mutant, exhibits profound
cellular defects that cannot be solely attributed to the absence of capsule (31, 32). We
therefore assayed additional characteristics of cells lacking Uut1.
We had already noticed that ugd1Δ mutant cells appeared smaller and less spherical
than WT cells and exhibited the aggregation typical of acapsular strains (Fig. 3A). Closer
examination of the uut1Δ mutant by transmission electron microscopy (TEM) conﬁrmed
these observations, and revealed the absence of the distinct morphological layers in the
cell wall (Fig. 7A) that are normally present in WT cells (11, 41–43). The mutant cell wall
also appeared less organized (Fig. 7A) and showed altered exposure of mannans as
detected by ConA binding, although dyes recognizing other components of the cell
wall bound the two strains similarly (Fig. S3). Furthermore, the cell membrane appeared
to make irregular contact with the internal surface of the cell wall, and the cells
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contained large vacuoles and abnormal intracellular inclusions, often associated with
the plasma membrane, whether they were grown in rich or nutrient-deﬁcient media
(Fig. 7A and Fig. S4). The contents of vacuoles or membranous inclusions were not
recognized by anti-GXM antibody in immunoelectron microscopy studies (Fig. S4).
In addition to marked abnormalities in cell morphology, the uut1Δ mutant was
highly susceptible to a range of stresses. It demonstrated temperature-sensitive growth
(shown for solid and liquid media in Fig. 7B and Fig. S5, respectively), which was
exacerbated by nutrient limitation (Fig. S5). Mutant cells also grew poorly in the
presence of SDS or high salt (Fig. 7B). Heterologous expression of the human UDP-GlcA
transporter, UGTrel7, did not restore growth under any of these conditions (Fig. S6).
Since pigment production correlates with resistance to environmental stress (44–
46), we assayed the ability of the mutant strain to produce melanin on medium
containing the precursor L-3,4-dihydroxyphenylalanine (L-DOPA). We observed no
melanization, however, even after 7 days of growth (Fig. 7C). In all phenotypic studies,
the complement restored growth or melanization to WT levels.
We next tested whether the observed mutant phenotypes would translate into
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FIG 4 Uut1 activity in vitro. (A and B) Substrate and exchange substrate speciﬁcity of Uut1. Proteolipo-
somes from cells without Uut1 (white bars) or with Uut1 (black bars), preloaded with 30 mM UMP (A) or
30 mM GMP (B), were incubated for 10 min with a mixture of the indicated nucleotide sugars, each at
50 M. Data were normalized to the total protein content of the proteoliposome preparations. (C)
Proteoliposomes from cells expressing Uut1, preloaded with 10 mM UMP, were incubated with UDP-GlcA
at the indicated concentrations for 2 min, and UDP-GlcA transport was measured as described in
Materials and Methods. (D) Proteoliposomes, preloaded as described above for panel C, were assayed
with 50 M UDP-GlcA for the times shown. Values are normalized to the Uut1 content of the
proteoliposome preparations (see Table S2 in the supplemental material). All values shown are the
means  SEMs (error bars) from four independent experiments.
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aberrant interactions with host cells. Using an automated imaging method (47), we
found that differentiated human monocytic cells (THP-1 cells) internalized the uut1Δ
mutant at signiﬁcantly higher rates than they internalized the WT, independent of
serum opsonization (Fig. 8A). The mutant was also more susceptible to killing after
internalization: host phagocytes completely cleared the uut1Δ mutant by 24 h, in
contrast to stable levels of the WT and the complemented strain (UUT1; Fig. 8B).
Our data suggested that the uut1Δ mutant would poorly evade recognition and
clearance by the host immune system and that it was unlikely to survive under host
nutrient and temperature conditions. To test this in vivo, we inoculated mice with the
WT, uut1Δ, or UUT1 strain intranasally to mimic the natural route of infection. The uut1Δ
mutant was cleared from the lungs by 15 days postinfection (dpi) (Fig. 9A), with no
fungi detected in the brain or spleen at that time (Fig. S7). The WT or the comple-
mented strain, in contrast, caused the mice to succumb to infection by 3 weeks
postinoculation (Fig. 9B).
DISCUSSION
We have discovered the ﬁrst fungal nucleotide sugar transporter that translocates
UDP-GlcA. This protein, Uut1, is critical for C. neoformans virulence, likely due to its role
in providing a key precursor for synthesis of the polysaccharide capsule and potentially
other glycoconjugates, and it is also notable for its substrate speciﬁcity. Importantly,
Uut1 has less than 12% identity at the protein level with its human counterpart, which
also does not compensate for deﬁciencies in the fungal mutant (see Fig. S6 in the
supplemental material).
FIG 5 UDP-GlcA metabolism. (A) UDP-GlcA synthesis and regulation. (B) Nucleotide sugar concentrations
in the uut1Δ mutant (black bars) compared to the WT control (white bars). Values are the averages 
SEMs for four independent replicates. Values that are signiﬁcantly different (P  0.01) by two-tailed
Student’s t test are indicated by two asterisks.
FIG 6 Transcription of UUT1 increases during capsule induction. The numbers of reads from RNA-seq
data (mean  SD) during capsule induction (see Materials and Methods) were normalized to their levels
at t  0, which were as follows: 125,691  8,645 for UUT1, 1,761,976  108,920 for UGD1, and
4,495,647 279,579 for ACT1 (included as a control). Values shown are compiled from three independent
experiments, each with RNA prepared from three biological replicates as in reference 74.
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Similar to other NSTs, Uut1 is localized to the secretory pathway. Our immunoﬂu-
orescence studies suggest that this protein occurs mainly in the ER (Fig. 6), like the
human transporter (UGTrel7) and in contrast to the more closely related, yet Golgi
apparatus-localized, plant transporter (UUAT1) (33, 48). This is surprising, because we
expect formation of mannose polymers to precede the addition of GlcA, and the
mannose donor enters the secretory pathway in the Golgi apparatus (30, 49, 50). It may
be that luminal UDP-GlcA progresses through the secretory pathway. Alternatively, the
distribution of protein upon heterologous expression in S. cerevisiaemay not accurately
reﬂect the native localization, for example because of expression level or the lack of
FIG 7 uut1Δ mutants exhibit defects in cell morphology and growth. (A) Electron micrographs of WT,
uut1Δ, and UUT1 strains grown in rich medium (left and middle columns, bar  1 m) with enlarged insets
(right column, bar  0.25 m). (B) Melanization of the indicated strains after growth on L-DOPA plates (see
Materials and Methods). lac1Δ cells do not melanize (75). (C) The indicated strains were grown overnight
at 30°C in YPD medium, and 5-l volumes of serially diluted strains (10-fold serial dilutions starting at
106 cells/ml) were spotted and grown on YPD or minimal medium under the conditions shown. Images of
the 30°C and 37°C plates were taken 2 and 3 days after inoculation, respectively.
FIG 8 Cells lacking Uut1 are more efﬁciently phagocytosed and killed by human cells than by wild-type
C. neoformans. (A) Phagocytic index (engulfed fungi/100 host cells) for fungi with or without serum
opsonization. (B) Fold change in CFU (comparing results at 24 h to results at 1 h) after internalization of
opsonized fungi by THP-1 cells. Data are means  SEMs for three biological replicates. Values that are
signiﬁcantly different (P 0.05) by one-way ANOVA and Tukey’s posthoc test are indicated by an asterisk.
ND, not detected.
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potential cryptococcal interaction partners. Furthermore, even if much of the protein is
retrieved to the ER, perhaps to serve transport-independent functions, some fraction
may remain in the Golgi apparatus (spatially separated from late Golgi proteins like
Sec7) and carry out transport there. Further analysis to determine localization of the
cryptococcal transporter must await the development of reliable subcellular imaging
methods for C. neoformans.
Uut1 is unique in its speciﬁcity for UDP-GlcA among cryptococcal nucleotide sugars.
Other known proteins that translocate UDP-GlcA also transport additional substrates in
vivo: UGTrel7 and UUAT1 transport UDP-GalNAc and UDP-GalA, respectively (33, 48),
while the Drosophila and C. elegans transporters, UST74c and SQV-7, recognize an even
wider range of UDP-sugars (22, 51). Another notable feature of Uut1 is its afﬁnity for
UDP-GlcA, which is signiﬁcantly above that of plant or human transporters, with a Km
of 0.6 M compared to 1.5 mM for UUAT1 and 4 M for UGTrel7 (33, 48). This low Km
relative to the measured cellular UDP-GlcA concentrations (Fig. 5B) suggests that Uut1
functions at a constant rate in both rich and nutrient-deﬁcient media. Meeting in-
creased demand for UDP-GlcA in the secretory pathway, for example under capsule-
inducing conditions, thus requires more Uut1, which is achieved by upregulation at the
transcriptional level (Fig. 6). The higher rates of UDP-GlcA transport out of the cytosol
could then reduce UDP-Xyl production and consequent inhibition of Ugd1, balancing
the system and maintaining stable UDP-GlcA levels (Fig. 5 and reported values above).
In the absence of Uut1, there is likely an elevated pool of cytosolic UDP-GlcA due to the
absence of transport and subsequent consumption, which leads to slightly increased
UDP-Xyl production in that compartment and consequent feedback inhibition on
Ugd1. Thus, total UDP-Glc, but not UDP-GlcA or UDP-Xyl, was signiﬁcantly higher in
uut1Δ cells than in WT cells.
Uut1 and the human transporter UGTrel7 overlap in subcellular localization, and
both translocate UDP-GlcA, yet UGTrel7 does not rescue the uut1Δ mutant phenotype.
At 550 amino acids, Uut1 is also roughly 70% longer than UGTrel7 and other NSTs,
mainly due to a unique extended N-terminal cytosolic domain (Fig. S1) that is absent
from the human and plant transporters and dispensable for transport activity (Fig. 4
and Fig. S2). It may be that this domain interacts with cryptococcal synthetic machinery
to efﬁciently channel substrates into the luminal compartment or performs other
functions speciﬁc to Uut1. Further studies of this unusual protein may elucidate
functional differences that could be exploited for therapeutic intervention.
Cells lacking the donor of Xyl, an abundant capsule component, display capsule
although the ﬁbers are short and deformed (32, 40). Since GlcA is less abundant than
Xyl in capsule polysaccharides, we originally expected to observe a similar phenotype
in uut1Δ cells. We were therefore surprised to observe that these cells completely
FIG 9 The uut1Δ mutant is severely attenuated for virulence. (A) Lung CFU of mice infected intranasally
with 5  104 cells of WT (white bars) or the uut1Δ mutant (black bars). Data shown are means  SDs for
three mice. Values that are signiﬁcantly different by two-tailed Student’s t test are indicated by bars and
asterisks as follows: *, P  0.05; **, P  0.01; ***, P  0.001. ND, not detected. (B) Survival of mice infected
as in panel A with the indicated strains (8 or 9 mice per strain).
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lacked capsule (Fig. 3 and Fig. S4). These unexpected results suggest that GlcA
modiﬁcation is a prerequisite for Xyl addition. This model is consistent with the greater
variability in GXM and GXMGal of capsule Xyl residues compared to GlcA and their
more distal position in GXMGal (11). An acapsular phenotype could also result if GlcA
incorporation is required for the extension of GXM’s mannose backbone or to inhibit
the degradation of unmodiﬁed mannose polymers.
Another possible explanation for the lack of capsule on uut1Δ cells is that GlcA
modiﬁcation is required for export of GXM and/or GXMGal, either directly by interacting
with trafﬁcking machinery or indirectly by enabling additional modiﬁcations (e.g., Xyl
incorporation [76–78]) required for recognition. The mutant cells do contain unusual
intracellular inclusions (Fig. 7 and Fig. S4), although their contents were not recognized
by anti-GXM antibody (Fig. S4). (The possibility that aberrant polymers are made but are
not recognized by the anti-GXM antibodies we tested remains, although none of these
antibodies are reported to require GlcA for binding [52, 53].) Finally, GlcA modiﬁcation
could be required for function of a protein involved in capsule synthesis (see below).
We observed numerous defects in the growth and morphology of cells lacking Uut1,
including cell wall disorganization and abnormal plasma membranes (Fig. 7 and
Fig. S3). This suggests a role for GlcA modiﬁcation beyond the capsule. Although GlcA
has not been detected thus far in surveys of cryptococcal protein-linked glycans or
glycolipids (54–57), the levels might be below the limits of detection of the methods
used. Glucuronidation could also potentially occur in additional contexts (e.g., the
cytosol). Further detailed characterization of cryptococcal glyconconjugates may elu-
cidate such mechanisms.
The lack of a GlcA donor in the secretory pathway drastically inﬂuences cryptococcal
interactions with the host. The resulting absence of the polysaccharide capsule may
expose normally hidden immunogenic components (Fig. S3) (58), while aberrant
glycosylation may also create novel immunoreactive epitopes. Both of these could lead
to the increased recognition and internalization of the uut1Δ mutant by macrophages
that we observe (Fig. 8). Internalized uut1Δ cells are also rapidly cleared both in vitro
(Fig. 8) and in vivo (Fig. 9), likely facilitated by the reduced ability of the uut1Δ mutant
to resist environmental stress. These observations suggest processes involving UDP-
GlcA synthesis as a potential target for intervention, which might exploit the unique
features of key proteins like Uut1 and the novel biology of the pathogen.
Our discovery of a highly speciﬁc, high-afﬁnity fungal UDP-GlcA transporter has
provided novel insights into cryptococcal biology. These studies have advanced our
understanding of the localization and sequence of glycan biosynthetic events and
supported the hypothesis that GlcA is incorporated into structures other than capsule
and that it plays integral roles in maintaining cellular homeostasis. This work thus sets
the stage for future studies in both cryptococcal pathogenesis and fundamental
glycobiology.
MATERIALS AND METHODS
Sequence and phylogenetic analyses. uut1 was identiﬁed by BLASTP searches against Cryptococ-
cus neoformans predicted proteins (Broad Institute; Cryptococcus neoformans var. grubii H99 database)
using known UDP-GlcA transporters from Arabidopsis thaliana (accession no. NP_196036.1), Caenorhab-
ditis elegans (accession no. NP_495436.1 and AT5G04160), Homo sapiens (accession no. NP_055954.1),
and Drosophila melanogaster (accession no. NP_524126.1). Multiple-sequence alignment (MUSCLE [59]),
phylogenetic analysis (PhyML [60]), and tree rendering (TreeDyn [61]) of Uut1, characterized UDP-GlcA
transporters (listed above), and other known cryptococcal nucleotide sugar transporters (NSTs) was done
using the online Phylogeny.fr program (http://www.phylogeny.fr/index.cgi) with default settings (62, 63).
The putative protein topology of Uut1 was predicted using the Constrained Consensus TOPology
prediction server (CCTOP; Institute of Enzymology, Budapest, Hungary) (64, 65) and visualized using
Protter (http://wlab.ethz.ch/protter/start/) (66). The predicted endoplasmic reticulum (ER) localization
signal was identiﬁed using LocSigDB (http://genome.unmc.edu/LocSigDB/) (67).
Cell growth. C. neoformans strains were grown at 30°C in YPD medium (1% [wt/vol] Bacto yeast
extract, 2% [wt/vol] Bacto peptone, 2% [wt/vol] dextrose) with shaking (230 rpm) unless otherwise noted.
For phenotypic analysis, cells from cultures grown overnight (O/N; 16 to 18 h) were washed in sterile
phosphate-buffered saline (PBS) and resuspended at 106 cells/ml in PBS, and 5-l aliquots of ﬁvefold
serial dilutions were plated and grown at 30°C or 37°C as indicated. Conditions tested included YPD
plates containing 0.01% SDS, 1.2 M NaCl, 1.2 M KCl, Tris (pH 8.8), 1.5 M sorbitol, 0.05% Congo red (CR),
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or 2% calcoﬂuor white (CFW). Samples were also tested on YNB medium (0.67% [wt/vol] yeast nitrogen
base without amino acids, 2% [wt/vol] glucose, 2% [wt/vol] agar, 25 mM sodium succinate [pH 4.0])
supplemented with 0.5 mM hydrogen peroxide (H2O2) or sodium nitrite (NaNO2) to test oxidative and
nitrosative stress sensitivity, respectively. Cell-associated melanin production was assayed by plating 5 l
of a solution of 106 cells/ml on agar plates containing 8 mg/ml KH2PO4, 2 mg/ml glucose, 2 mg/ml
L-glycine, 1 g/ml D-biotin, 1 g/ml thiamine, 0.92 mg/ml MgSO4 · 7H2O, and 0.4 mg/ml L-3,4-
dihydroxyphenylalanine (L-DOPA; Sigma-Aldrich).
To determine the growth rates of various strains, cells from O/N cultures were washed in sterile PBS
and resuspended at 105 cells/ml in 30 ml of YPD, YNB, Dulbecco modiﬁed Eagle medium (DMEM), or RPMI
1640 medium at 30°C or 37°C as indicated. Triplicate samples were taken at regular intervals and counted
with a hemocytometer.
C. neoformans strains and plasmids. To generate the uut1Δ mutant, we replaced UUT1 in the
C. neoformans KN99 wild-type (WT) strain with a nourseothricin (NAT) resistance marker, using a split
marker strategy (68). Transformants of interest were identiﬁed by resistance to NAT and validated by PCR
veriﬁcation of gene replacement. We used a similar strategy to replace the NAT deletion cassette with
UUT1 (ampliﬁed from KN99 cDNA) or UGTREL7 (ampliﬁed from a pMKIT-neo hUGTrel7-HA plasmid [48]),
in tandem with a Geneticin (G418) resistance marker. Transformants resistant to G418 and sensitive to
NAT were veriﬁed by PCR.
Saccharomyces cerevisiae localization. UUT1 was ampliﬁed from C. neoformans KN99 cDNA,
cloned into the copper-inducible expression vector pYEScupFLAGK (26), and transformed into S. cerevi-
siae strain Sec7-3xGFP (from Benjamin S. Glick, University of Chicago) using lithium acetate. After O/N
growth in synthetic complete (SC) medium minus uracil (URA), cultures were adjusted to 0.5 mM CuSO4
and cultured for 1 h. The cells were ﬁxed in 1% paraformaldehyde for 30 min, washed, resuspended in
a 0.1 M KPO4 (pH 6.5)–1.2 M sorbitol buffer, and then incubated for 15 min in buffer supplemented with
-mercaptoethanol (2% [vol/vol]) and zymolyase (100 g/ml; Sigma-Aldrich). Fifteen-microliter aliquots
of buffer-washed cells were then spotted onto polylysine-coated slides (Electron Microscopy Sciences),
and the slides were incubated for 10 min and immediately plunged ﬁrst in methanol for 5 min and then
in acetone for 30 s. The samples were blocked with 5% goat serum in PBS for 30 min and stained O/N
at 4°C with anti-FLAG (mouse antibody diluted 1:1,000; Invitrogen) and anti-Kar2p/BiP antibody (rabbit
antibody 1:1,000; from Jeff Brodsky, University of Pittsburgh). Finally, cells were incubated for 2 h with
Alexa Fluor 594-tagged goat anti-mouse IgG (Thermo Fisher Scientiﬁc), Alexa Fluor 488-tagged goat
anti-rabbit IgG (Thermo Fisher Scientiﬁc), and 4=,6=-diamidino-2-phenylindole (DAPI) (Thermo Fisher
Scientiﬁc), and viewed with a Zeiss Axioskop2 MOT Plus microscope (Carl Zeiss Microscopy, LLC). Where
not speciﬁed, all steps were performed at room temperature (RT).
Capsule induction and visualization. Cultures of C. neoformans grown in YPD O/N were collected
by centrifugation (3,000  g, 5 min) and washed twice with sterile PBS. The cells were then resuspended
in DMEM at 106 cells/ml in T-75 tissue culture ﬂasks or 24-well plates and incubated at 37°C with 5% CO2
for 24 h to induce production of capsule. Induced cells were collected, washed, and resuspended in PBS,
mixed with 1.5 parts India ink (Chartpak, Inc.), and viewed with a Zeiss Axioskop2 MOT Plus microscope
(Carl Zeiss Microscopy, LLC).
GXM detection. Cell wall-associated and shed GXM were visualized by ﬂuorescence microscopy and
immunoblotting, respectively. To visualize capsule on cells, the strains were induced as described above
for 24 h, ﬁxed for 1 h in 3.7% formaldehyde, washed in PBS, and then incubated for 1 h at RT with
1 mg/ml of anti-GXM monoclonal antibody (MAb) 3C2, 2H1, 3O2, 339, or F12D2 (from Thomas R. Kozel,
University of Nevada School of Medicine) conjugated to Alexa Fluor 488. Stained cells were washed twice
with PBS, resuspended in PBS, and examined on a Zeiss Axioskop 2 MOT Plus microscope. All samples
from each experiment were imaged with identical acquisition settings. To analyze shed GXM, strains were
induced for 90 min or 24 h before cells were removed by centrifugation. The supernatant fractions were
then denatured with heat (60°C for 5 min), resolved on agarose gels, transferred onto a positively
charged nylon membrane, and immunoblotted with 1 g/ml anti-GXM MAb 3C2, 2H1, F12D2, or 339 as
described in reference 69. The GXM content of the supernatant fractions was quantiﬁed by ELISA as
described in reference 70 using MAb 339 and F12D2.
Heterologous expression, reconstitution, and transport assays. The UUT1 coding region was
synthesized into pUC57-Amp by Genewiz, ampliﬁed by PCR without the native stop codon, and
introduced into the pENTR/SD/D-TOPO vector (Life Technologies) according to the manufacturer’s
protocols to generate pENTR-UUT1. Recombination of the entry clone with destination vector pYES-
DEST52 (Life Technologies) using LR clonase II (Life Technologies) produced a C-terminal His/V5 epitope
fusion that was veriﬁed by sequencing before transformation into S. cerevisiae strain INVSc1 (Thermo
Fisher Scientiﬁc). To verify heterologous protein expression, 2.5 g of the proteoliposomes were resolved
by SDS-PAGE and analyzed by immunoblotting with anti-V5 antibody (Thermo Fisher Scientiﬁc) as
previously described (71). Reconstitution of microsomal proteins and transporter activity assays were also
carried out as previously described (71). UDP-GlcA transport was measured at the UDP-GlcA concentra-
tions and times indicated, and kinetic parameters were calculated by nonlinear regression using the
Prism 6 application (GraphPad Software). Measured Uut1 content (see Table S2 in the supplemental
material) was used to determine turnover rate.
Quantiﬁcation of nucleotide sugars by mass spectrometry. Nucleotide sugars were extracted
from approximately 50 mg of ground cells (wet weight) according to previous methods (72). Liquid
chromatography-tandem mass spectrometry (LC-MS/MS) was performed using porous graphitic carbon
as the stationary phase on a 1100 series high-performance liquid chromatography (HPLC) system (Agilent
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Technologies) and a 4000 QTRAP LC-MS/MS system (Sciex) equipped with a TurboIonSpray ion source
using methods previously described (73). Four biological replicates were analyzed, each in duplicate.
Fungal gene expression. Wild-type cells cultured in YPD medium were induced for capsule as
described above and sampled at 0, 1.5, 3, 8, and 24 h for RNA isolation and sequencing. See reference
74 for details.
Electron microscopy. Strains were grown in YPD medium or under capsule-inducing conditions,
collected by centrifugation (3,000  g, 5 min), ﬁxed for 1 h at RT with 2% glutaraldehyde (Polysciences
Inc.) in 100 mM phosphate buffer (pH 7.2), and then incubated for 1 h in 1% osmium tetraoxide (OsO4;
Polysciences Inc.). Following dehydration with ethanol and propylene oxide, the cells were embedded in
Eponate 12 resin (Tel Pella Inc.), and 70- to 90-nm sections were cut with a UCT ultramicrotome (Leica
Microsystems Inc.). Sections were stained with uranyl acetate and lead citrate for visualization with a JEOL
1200EX transmission electron microscope (JEOL Inc.).
For immunoelectron microscopy, cells were ﬁxed and labeled as described in reference 17. Brieﬂy,
induced cells were ﬁxed in glutaraldehyde as described above, washed in citrate buffer (pH 6.0), and
treated with lysing enzymes from Trichoderma harzianum (Sigma-Aldrich) in the same buffer for 30 min
before being washed in 0.1 M phosphate buffer (pH 7.0), and postﬁxed in 1% OsO4. Ethanol-substituted
samples were then substituted in propylene oxide and embedded in Eponate 12 resin. Sections were
blocked with 5% fetal bovine serum (FBS) (Thermo Fisher Scientiﬁc) in piperazine-N,N=-bis(2-
ethanesulfonic acid) (PIPES) buffer (pH 7.0) for 30 min, labeled with the anti-GXM MAb 3C2 for 1 h,
washed in blocking buffer, and incubated with 12-nm-gold-conjugated goat anti-mouse IgG (Jackson
Immuno Research). Sections were then washed in PIPES buffer and water, stained with uranyl acetate and
lead citrate, and viewed with a JEOL JEM-1400Plus 120-kV transmission electron microscope (JEOL Inc.).
Cell wall staining. For eosin Y staining, O/N cultures were washed, diluted to 107 cells/ml in
McIlvaine’s buffer (pH 6.0), and incubated with 250 g/ml eosin Y for 15 min. For the other dyes, the cells
were washed, diluted to 107 cells/ml in PBS, and stained for 15 min with 100 g/ml calcoﬂuor white
(CFW) (ﬂuorescent brightener 28; Sigma), 30 g/ml concanavalin A (ConA)-ﬂuorescein isothiocyanate
(FITC) (Sigma), or 1:10,000 dilution Pontamine (Pontamine fast scarlet 4B; Bayer Co.). The cells were then
washed in PBS and imaged with a Zeiss Axioskop2 MOT Plus microscope.
Macrophage assays. Macrophage phagocytosis and survival of fungal strains was quantiﬁed as
described in reference 39. Brieﬂy, cells were grown in YPD medium, collected by centrifugation, washed,
and opsonized with human serum before incubation with differentiated THP-1 macrophages for 1 h. To
measure fungal uptake by phagocytes, host cell cytosol and nuclei and fungal walls were stained, and
samples were imaged on a Cytation3 plate reader (BioTek) and analyzed using IN Cell Developer Toolbox
1.9.2 (GE Healthcare Life Sciences). For survival assays, samples were washed twice with PBS and lysed
either immediately or after a 24-h incubation, and the lysate was plated on YPD agar for CFU counts.
Assay results for the uut1Δ mutant were compared to those for the wild-type and complemented strains
by one-way analysis of variance (ANOVA) with Tukey’s posthoc test.
Animal studies. Fungal strains to be tested were cultured O/N in YPD medium, washed in sterile PBS,
and diluted to 106 cells/ml in sterile PBS. Four- to 6-week-old female A/JCr mice (National Cancer
Institute) were then intranasally inoculated with 50-l aliquots of each strain. Groups of three mice
infected with the WT strain and three mice infected with the uut1Δ mutant were sacriﬁced at 6, 12, and
15 days postinoculation. Initial inocula and organ (lung, brain, spleen) homogenates were plated for CFU,
and organ burden was analyzed by Student’s t test. Additional groups of eight mice were infected with
WT, uut1Δ, and UUT1 strains, weighed daily, and sacriﬁced once they lost 20% of their body weight
relative to peak weight or at day 50. Survival curves were compared using a log rank test in GraphPad
Prism. All studies were performed in compliance with institutional guidelines for animal experimentation.
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